All In Biotech

Drug Trial Radar · NCT07858500

Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE)

Real-world Clinical Outcomes, Patient Characteristics, and Treatment Patterns Among Patients With Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-negative, Claudin-18 Isoform 2-positive Gastric or Gastroesophageal Junction Adenocarcinoma Treated With Zolbetuximab or Other First Line Treatments: A Cohort Study Using Secondary Data in Europe and Canada

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Jan 31, 2027

Primary completion

Jun 30, 2029

Study completion Jun 30, 2029

Sponsor

Lead sponsor
Astellas Pharma Europe Ltd.Astellas (ALPMY)
Sponsor type
Industry
First posted
Oct 5, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There is an unmet medical need to treat people with advanced cancer in the stomach, or where the food pipe joins the stomach. These conditions are known as advanced gastric cancer or advanced gastroesophageal cancer (GEJ for short). Zolbetuximab is an approved treatment for people with advanced stomach (gastric) cancer or advanced GEJ cancer. Some people with stomach or GEJ cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab works by attaching to the Claudin 18.2 protein in their tumor. This switches on the body's immune system to attack the tumor. The main aim of the study is to collect information about zolbetuximab and other cancer treatments in people with advanced gastric or GEJ cancer. This includes safety information, how long people respond to treatment and how long people live for without their cancer getting worse. This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the sponsor (Astellas). This study will use information from European and Canadian health registries and databases to learn more about people with advanced gastric or GEJ cancers who used zolbetuximab and other cancer treatments. The entire study will last about 4 years.

Conditions

  • Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
  • Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
  • Metastatic Gastric Adenocarcinoma or Cancer
  • Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

  • Zolbetuximab ExposureDrug

    Real-world exposure to zolbetuximab.

  • Platinum-based Chemotherapy ExposureDrug

    Real-world exposure to platinum-based chemotherapy.

  • 1L Treatment Not Containing Zolbetuximab ExposureDrug

    Real-world exposure to 1L treatment not containing zolbetuximab.

  • Fluoropyrimidine-based Chemotherapy ExposureDrug

    Real-world exposure to fluoropyrimidine-based chemotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort A: real-world overall survival (rwOS)Time frame: From the point of initiating 1L treatment, assessed up to 4 years
  2. Cohort A: real-world progression-free survival (rwPFS)Time frame: From the point of initiating 1L treatment, assessed up to 4 years
  3. Cohort A: real-world time to next treatment (rwTTNT)Time frame: From the point of initiating 1L treatment, assessed up to 4 years
  4. Cohort A: real-world time to next treatment or death (rwTTNTD)Time frame: From the point of initiating 1L treatment, assessed up to 4 years
  5. Cohort A: real-world time to progression (rwTTP)Time frame: From the point of initiating 1L treatment, assessed up to 4 years
  6. Cohort A: real-world duration of response (rwDOR)Time frame: From the point of initiating 1L treatment, assessed up to 4 years
  7. Cohort A: real-world response rate (rwRR)Time frame: From the point of initiating 1L treatment, assessed up to 12 months
  8. Cohort A: real-world disease control rate (rwDCR)Time frame: From the point of initiating 1L treatment, assessed up to 12 months
  9. Cohort A: real-world tumor growth rate (rwTGR) prior to 1L treatmentTime frame: Day 1
  10. Cohort A: rwTGRTime frame: From point of initiating 1L treatment, assessed up to 4 years
  11. Cohort A: number of records of specified adverse events (AEs)Time frame: From the point of initiating 1L treatment, assessed up to 4 years
  12. Cohort A: duration of specified AEsTime frame: From the point of initiating 1L treatment, assessed up to 4 years
  13. Cohort A: time to first specified AE recordTime frame: From the point of initiating 1L treatment, assessed up to 4 years
  14. Cohort A: number of participants with serious adverse events (SAEs)Time frame: From the point of initiating 1L treatment, assessed up to 4 years
  15. Cohort A: number of SAEs experienced per participantTime frame: From the point of initiating 1L treatment, assessed up to 4 years
  16. Cohort A: number of specific SAETime frame: From the point of initiating 1L treatment, assessed up to 4 years
  17. Cohort A: number of records per participant of specific SAETime frame: From the point of initiating 1L treatment, assessed up to 4 years
  18. Cohort A: time to first SAE recordTime frame: From the point of initiating 1L treatment, assessed up to 4 years
  19. Cohort A: number of participants with inpatient hospitalizationsTime frame: From the point of initiating 1L treatment, assessed up to 4 years
  20. Cohort A: number of inpatient hospitalizations with ICU stay per participantTime frame: From the point of initiating 1L treatment, assessed up to 4 years
  21. Cohort A: number of inpatient hospitalizations with admission via accident and emergency (A&E) per participantTime frame: From the point of initiating 1L treatment, assessed up to 4 years
  22. Cohort A: duration of inpatient hospitalizationsTime frame: From the point of initiating 1L treatment, assessed up to 4 years
  23. Cohort A: primary diagnoses associated with inpatient hospitalizationsTime frame: From the point of initiating 1L treatment, assessed up to 4 years
  24. Cohort A: number of participants receiving at least one antiemeticTime frame: From the point of initiating 1L treatment, assessed up to 4 years
  25. Cohort A: number of antiemetics prescribed or dispensed to participantsTime frame: From the point of initiating 1L treatment, assessed up to 4 years
  26. Cohort A: time to prescription or dispensation of any antiemetic drugsTime frame: From the point of initiating 1L treatment, assessed up to 4 years
  27. Cohort A: type of antiemetic drug received immediately prior to 1L treatmentTime frame: Day 1
  28. Cohort A: type of antiemetic drug receivedTime frame: From the point of initiating 1L treatment, assessed up to 4 years
  29. Cohort A: antiemetic drugs received immediately prior to 1L treatmentTime frame: Day 1
  30. Cohort A: antiemetic drugs receivedTime frame: From the point of initiating 1L treatment, assessed up to 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Institution

    Alberta, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.